We sifted through stock screeners, online rankings, and ETFs to compile a list of 30 cancer stocks. We then selected the top ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old. The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

Obviously, Dupixent in COPD has a broader label ... They overlap ever so slightly, I think, in the above 300 EOS level in the Type 2 COPD patient population. But I think the compliment of the ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Dupixent continues to be a significant growth driver for Regeneron. The company recently received approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European ...

SNY earnings call for the period ending December 31, 2024.

The company's flagship products include Eylea for eye diseases and Dupixent for various inflammatory conditions. In the second quarter of 2024, Regeneron demonstrated strong performance ...

The company’s other growth driver, Dupixent, is also doing well, helping shrug off sales slowdown in different drugs. The fact that the US Food and Drug Administration has approved using ...

GE Hitachi Nuclear Energy (GEH), a business of GE Vernova, has joined the coalition of utility companies that are working to accelerate the deployment of BWRX-300 small modular reactors in the ...

300 is a 2007 fantasy war movie directed by Zack Snyder, which is based on a graphic novel of the same name by Frank Miller. The graphic novel and the movie tell the true story of King Leonidas I ...

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.